Recently, Jinhe Biotechnology Co., Ltd. announced its plan to establish a wholly-owned subsidiary with an investment of RMB 50 million in self-raised funds. This move aims to further optimize the company’s industrial layout, expand into new business areas, and enhance its overall competitiveness. The new subsidiary will focus on research, development, and production in fields such as biopharmaceuticals, animal health products, or related high-tech sectors, with its specific business scope to be refined based on market conditions and strategic priorities.As a leading Chinese enterprise in animal health and biological products, Jinhe Biotech has consistently increased its investments in technological innovation and vertical integration. Establishing a wholly-owned subsidiary will not only help the company better integrate resources and improve operational efficiency but also allow it to gain a first-mover advantage in niche markets. Additionally, operating as an independent legal entity will enable the new company to more flexibly access capital markets, attract specialized talent, and accelerate the commercialization of technological innovations.The investment amount represents a manageable portion of the company’s most recently audited net assets and is not expected to significantly impact its financial condition or core operations. Jinhe Biotech stated that it will continue to focus on its core business while steadily advancing a diversified development strategy to deliver long-term value to shareholders.
近日，金河生物科技股份有限公司发布公告称，拟以自有资金5000万元人民币投资设立一家全资子公司。此举旨在进一步优化公司产业布局，拓展业务领域，提升整体竞争力。新设子公司将聚焦于生物医药、动物保健品或相关高新技术领域的研发与生产，具体经营范围将根据市场环境和公司战略进行细化。金河生物作为国内领先的动物保健品和生物制品企业，近年来持续加大在科技创新和产业链延伸方面的投入。设立全资子公司不仅有助于公司整合资源、提高运营效率，还能为其在细分赛道中抢占先机。此外，通过独立法人主体运作，新公司有望更灵活地对接资本市场、吸引专业人才，并加速科技成果转化。此次投资金额占公司最近一期经审计净资产的一定比例，但不会对公司财务状况和主营业务造成重大影响。金河生物表示，未来将继续围绕核心主业，稳步推进多元化发展战略，为股东创造长期价值。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/8080.html